Clinical Trials Directory

Trials / Completed

CompletedNCT01746914

Morphofunctional Lung Analysis by PET and CT After Lung Transplantation

Morphofunctional Lung Analysis by Positron Emission Tomography and Computed Tomography After Lung Transplantation

Status
Completed
Phase
Study type
Observational
Enrollment
30 (actual)
Sponsor
Policlinico Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

72 hours after lung transplantation, patients undergo a positron emission tomography (PET) scan and a computed tomography (CT) scan in order to analyse lung function and morphology. Aim of the study is to analyse complications onset (in particular primary graft dysfunction), and evaluate 90 days mortality after lung transplantation.

Detailed description

Pulmonary transplantation is considered as a lifesaving procedure in end-stage pulmonary disease. However morbidity and mortality after lung transplantation are still significant. Primary graft dysfunction (PGD) is the main cause of early death. PGD is similar to acute lung injury (ALI)/ acute respiratory distress syndrome (ARDS): oxygenation is compromised, pulmonary compliance is decreased, chest Rx shows several infiltrates, and alveolar damage is present. 25% of patients develops PGD within 72 hours from transplantation and 30 days mortality is eight times higher in patients who develop PGD. 72 hours after lung transplantation, patients, whose clinical condition allow to bring them to nuclear medicine department, will undergo pulmonary computed tomography (CT) to study lung morphology and measure lung recruitability and positron emission tomography (PET) to study lung functionality and estimate lung inflammation. Aim of this study is to investigate the onset of PGD and other complications and to determine 72 hours and 90 days mortality after lung transplantation.

Conditions

Timeline

Start date
2013-01-01
Primary completion
2014-07-01
Completion
2016-01-01
First posted
2012-12-11
Last updated
2016-03-30

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT01746914. Inclusion in this directory is not an endorsement.